The SARS-CoV-2 pandemic has affected more than 70 million people worldwide and resulted in over 1.5 million deaths. A broad deployment of effective immunization campaigns to achieve population immunity at global scale will depend on the biological and logistical attributes of the vaccine. Here, two adeno-associated viral (AAV)-based vaccine candidates demonstrate potent immunogenicity in mouse and nonhuman primates following a single injection. Peak neutralizing antibody titers remain sustained at 5 months and are complemented by functional memory T-cells responses. The AAVrh32.33 capsid of the AAVCOVID vaccine is an engineered AAV to which no relevant pre-existing immunity exists in humans. Moreover, the vaccine is stable at room temperature for at least one month and is produced at high yields using established commercial manufacturing processes in the gene therapy industry. Thus, this methodology holds as a very promising single dose, thermostable vaccine platform well-suited to address emerging pathogens on a global scale.

中文翻译：

---

基于 AAV 的室温稳定单剂量 COVID-19 疫苗在小鼠和非人类灵长类动物中的免疫原性

SARS-CoV-2 大流行已影响全球超过 7000 万人，并导致超过 150 万人死亡。在全球范围内广泛部署有效的免疫运动以实现人口免疫将取决于疫苗的生物学和后勤特性。在这里，两种基于腺相关病毒 (AAV) 的候选疫苗在单次注射后在小鼠和非人类灵长类动物中表现出强大的免疫原性。峰值中和抗体滴度保持 5 个月，并由功能性记忆 T 细胞反应补充。AAVCOVID 疫苗的 AAVrh32.33 衣壳是一种工程化 AAV，在人类中不存在相关的预先存在的免疫力。而且，该疫苗在室温下可稳定至少一个月，并且使用基因治疗行业中已建立的商业制造工艺以高产量生产。因此，这种方法是一个非常有前途的单剂量、热稳定的疫苗平台，非常适合在全球范围内应对新出现的病原体。